SciSparc Ltd. (SPRC)
- Previous Close
4.95 - Open
5.27 - Bid 3.61 x 200
- Ask 6.48 x 200
- Day's Range
5.00 - 5.27 - 52 Week Range
2.98 - 80.10 - Volume
11,576 - Avg. Volume
190,469 - Market Cap (intraday)
2.951M - Beta (5Y Monthly) 2.44
- PE Ratio (TTM)
0.05 - EPS (TTM)
98.07 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution. The company sells hemp seed oil-based products and others. The company has an agreement with Procaps to develop and commercially manufacture SCI-110 and palmitoylethanolamide oral tablets CannAmide in softgel capsule form. It also has an agreement with The Israeli Medical Center for Alzheimer's to conduct a phase IIa clinical trial to evaluate the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer's disease and agitation; and a collaboration with Clearmind Medicine Inc. The company was formerly known as Therapix Biosciences Ltd. and changed its name to SciSparc Ltd. in January 2021. SciSparc Ltd. was incorporated in 2004 and is headquartered in Tel Aviv-Yafo, Israel.
scisparc.com3
Full Time Employees
December 31
Fiscal Year Ends
Healthcare
Sector
Biotechnology
Industry
Recent News
View MorePerformance Overview
Trailing total returns as of 2026-09-11, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Earnings Trends
View MoreStatistics
View MoreValuation Measures
Market Cap
Enterprise Value
Trailing P/E
Forward P/E
PEG Ratio (5yr expected)
Price/Sales (ttm)
Price/Book (mrq)
Enterprise Value/Revenue
Enterprise Value/EBITDA
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-60.68%
Return on Equity (ttm)
-178.39%
Revenue (ttm)
856k
Net Income Avi to Common (ttm)
-12.18M
Diluted EPS (ttm)
98.07
Balance Sheet and Cash Flow
Total Cash (mrq)
4.59M
Total Debt/Equity (mrq)
7.11%
Levered Free Cash Flow (ttm)
833k
Compare
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
